Adaptimmune Therapeutics' P/S ratio remains below industry m...
Adaptimmune Therapeutics' P/S ratio remains below industry median despite share price surge. Its forecast for shrinking revenue, unlike industry peers predicting growth, justifies the low P/S ratio. Hard to foresee a strong share price rise soon under these conditions.
Adaptimmune Therapeutics Plc's (NASDAQ:ADAP) Shares Bounce 29% But Its Business Still Trails The Industry
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment